Clin2
NCT07771530Worth exploringRecruiting

Medication or dog therapy for PTSD symptoms

PTSDPosttraumatic Stress Disorder

Treatments studied

Part of Mental health clinical trials.

This study tests whether a combination of two medications (reboxetine and Ritalin) is more effective than dog-assisted therapy for reducing PTSD symptoms. Participation involves either taking the medications or attending dog therapy sessions.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
160 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old
  • You have been diagnosed with PTSD (per DSM-IV or DSM-5 criteria)
  • If you take any psychiatric medication, it must be at a stable dose for at least 1 month before the study starts
  • You do not have heart problems or other conditions that make these medications unsafe for you

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05133804Recruiting· Phase 2
Testing two medications for PTSD attention and emotions

This Phase 2 study tests whether reboxetine or methylphenidate can improve attention and emotional or sensory problems in adults with post-traumatic stress disorder (PTSD). You may be eligible if you have a confirmed PTSD diagnosis and are able to meet medication and safety requirements.

Afula
NCT07664631Not yet recruiting· Phase 1
Testing stimulant medications for PTSD

This study tests whether stimulant medications can help treat PTSD symptoms. Researchers want to see if these medications are safe and effective for people with PTSD.

Chicago, Illinois
NCT06418178Recruiting· Phase 2
Optimizing MDMA therapy dose for PTSD in veterans

This trial tests different doses of MDMA (a drug sometimes called 'ecstasy') combined with therapy to see which dose works best for treating PTSD in veterans. The goal is to find a safer, more effective dose to help reduce PTSD symptoms.

The Bronx, New York
NCT07704762Not yet recruiting· Phase 2
MDMA-assisted therapy for PTSD in military members

This trial tests if MDMA (a drug that can help with therapy) along with talk therapy can help military members with PTSD. It is designed for active duty, National Guard, or Reserve service members who have had PTSD for at least six months.

NCT05746572Enrolling by invitation· Phase 2
MDMA-assisted therapy plus exposure therapy for PTSD

This Phase 2 study tests whether MDMA combined with therapy that uses exposure (gradual confronting of trauma memories) can reduce PTSD symptoms. It may help people who meet PTSD criteria, can follow strict safety rules, and can complete medicine-session monitoring.

Atlanta, Georgia
NCT05837845Recruiting· Phase 2
MDMA plus therapy versus therapy alone for severe PTSD

This Phase 2 study compares MDMA-assisted Cognitive Processing Therapy (a structured talk-therapy) to Cognitive Processing Therapy alone for Veterans with severe PTSD. It aims to see whether adding MDMA helps reduce PTSD symptoms and improve recovery.

Palo Alto, California

Hear when a new Posttraumatic Stress Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.